Short description
Tolero Pharmaceuticals is a biopharmaceutical company that develops novel therapeutics to treat cancer and other life-threatening diseases.
Description
Tolero Pharmaceuticals is a biopharmaceutical company that discovers and develops novel therapeutics to treat and cure cancer and other life-threatening diseases in the United States. Its products include TP-0413 that targets a signaling pathway complicated in the regulation of serum iron levels for individuals suffering from chronic inflammatory diseases, such as cancer and rheumatoid arthritis; TP-0829, which targets a vital component of the B-cell receptor signaling pathway for the treatment of B-cell lymphomas, B-cell leukemia, and multiple myeloma; and TP-0903, a dual-targeted agent that inhibits two signaling pathways for pancreatic cancer cell growth and survival, and for the maintenance of the tumor stromal cells. The company’s products also comprise TP-0227 that targets a signaling pathway deregulated in cancer cells particularly in endometrial carcinomas; and TP-1149 which targets a cellular mechanism to render myeloma cells resistant to current therapeutic approaches. Tolero Pharmaceuticals, Inc. has a strategic partnership with MannKind Corporation.
The company was founded in 2011 and is based in Salt Lake City, Utah.
Last funding
Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Salt Lake City, Utah, United States, North America
Founded on
January 1, 2011
Closed on
December 21, 2016
Exited on
December 21, 2016
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$56378 - 90123
Sign in for full access
Investors
Cannot Access
Sign in for full access
Founders
Dallin M. Anderson, David J. Bearss